What are the limitations of the Pufulete (Mohiud) study?
The limitations of the Pufulete (Mohiud) study include preference weights of EQ-5D scores being based on subjects region of origin rather than UK tariffs, disease progression not being captured in the model, Austrian payer perspective, EQ-5D not being used to capture quality of life, costs and effects being discounted at 5%, cost of GP visits and drug costs not being collected and not included in the analysis of the clinical trial phase.